Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback on this new experience.Tell us what you think(opens in new tab/window)

Elsevier
Publish with us

Dr. V. Craig Jordan

DVCJ

Dr. V. Craig Jordan

Author profile(opens in new tab/window)

Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Previously, he was Chief Scientific Officer and Vice President of Oncology at Georgetown University's Lombardi Comprehensive Cancer Center. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant antihormone therapy. More recently, his work has branched out into the prevention of multiple diseases in women with the discovery of the selective estrogen receptor modulator (SERM) group of drugs. Currently, she plans to develop a new Hormone Replacement Therapy (HRT) for postmenopausal women that prevents breast cancer and does not increase the risk of breast cancer. Affiliations and Experience Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.